BRAF and melanoma: A multi-centric study of BRAF inhibitor-resistant melanoma tissue samples, analyzed after disease progression, most detected secondary genomic alterations in the MAPK/ERK signaling pathway, BRAF copy number gains and BRAF alternative splicing, as mechanistic drivers of resistance.